The earliest clinical trials to test the hypothesis that chemotherapy given as an adjuvant to surgery might improve prognosis were started a quarter of a century ago,2 but it was not until the mid-1970s that widespread interest in this approach was stimulated by the initial results of two prospective randomised trials in patients with spread to the axillary nodes. The first, run by the National Surgical Adjuvant Breast Project in the United States, used a two year course of single agent melphalan,3 and the second, based in Milan, used a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for More recently, the Milan CMF trial has been repeated in Britain by the Guy's-Manchester group, and this may eventually clarify some of the uncertainties of the original. So far a delay in recurrence of the tumour has emerged for treated patients but without a significant difference in survival.10 Likewise a West Midlands group comparing a five drug regimen containing doxorubicin (Adriamycin) against no systemic treatment1' and a British multicentre group using a four drug combination12 have both failed to show any significant survival benefit so far. In the United States Cooper et al have reported what seems to be an impressive 80% five year survival for patients with a poor prognosis with spread to four or more axillary nodes treated for nine months with a five drug combination.'3 The study was, however, not randomised and was based on only a few patients. A much larger, randomised multicentre trial has recently reported Cooper's combination to be superior to CMF in terms of interval free of relapse, but results with both regimens are considerably worse than in Cooper's original study.14 Two other American studies have claimed survival advantages for combinations containing doxorubicin but again neither was randomised.15 16 Many other trials have been started in the wake of the initial melphalan and CMF results, but an unfortunate consequence of all the premature optimism was that most abandoned non-treatment control arms on alleged "ethical" grounds, and thus cannot now clarify this critical question of difference in survival.
An important aspect of continued claims for so called "benefit" is that these are nearly always based not on real prolongation of survival, which ought to be the main aim of adjuvant treatment, but on what has come to be called "relapse free survival," a euphemistic term which simply measures time to recurrence of the tumour. It is hardly surprising that chemotherapy which achieves temporary delay in the growth of tumours in most patients with overt metastatic disease will do the same when the disease is subclinical, and the continued excitement generated each time a new trial shows a postponement of recurrence is hard to understand. An increase in "relapse free survival" is of no true survival benefit if it is bought at the expense of a shorter interval between relapse and death, as at least one trial of adjuvant oophorectomy'7 and a chemotherapy trial18 have already shown. In such circumstances there are positive arguments for withholding chemotherapy until relapse: its effectiveness can then be measured in terms of response of the tumour and patients already cured by the original local treatment are spared unnecessary further toxic treatment with uncertain long term sequelae.
The only argument in favour of treatment that delays recurrence irrespective of survival effect might be that the severe psychological blow of relapse is postponed. This must be weighed against the morbidity of treatment. Adjuvant chemotherapy is frequently stated by its advocates to be well tolerated with "acceptable" toxicity. This is not the experience of all clinicians, nor are such claims substantiated by independent observers. In a British study of self assessment questionnaires completed by patients at home 79(0 of patients reported side effects severe enough to interfere with life style and 290o volunteered that the experience could never be gone through again.19 An American study found that 780`of patients treated with a standard regimen of CMF suffered severe nausea and vomiting, with more than half developing anticipatory vomiting; most strikingly, 300 could not continue treatment, presumably despite being told that it might prolong life. 20 Other trials have shown that psychiatric morbidity is much commoner in patients treated with CMF than in untreated controls.2' 22 What are clinicians and their patients to make of these current uncertainties ? Attitudes to the management of breast cancer are too often dominated by a slavish pursuit of marginal and indeed arguable differences in survival with scant regard for the morbidity of treatment. Value judgments are needed here. Prolonged adjuvant chemotherapy certainly appears to delay recurrence and may on limited data have a small survival influence in some subgroups. But there is no convincing evidence of the kind of substantial survival advantage which might justify cost and above all chronic morbidity, and suggestions that it is unethical to withhold such treatment are nonsense. That is not to say that small improvements in survival do not matter if the price paid is acceptable. Early results with adjuvant tamoxifen are showing delays in recurrence reminiscent of the initial results with melphalan and CMF but with minimal side effects.23 Indeed, the fact that most trials of chemotherapy have shown a difference predominantly or even solely in premenopausal women suggests that these drugs too may be operating in part through an endocrine effect; certainly they cause suppression of ovarian function with amenorrhoea. 24 23 The apparent efficacy of a six day postoperative course of cyclophosphamide with low morbidity used in the Norwegian trial9 cannot be ignored; short-term postoperative chemotherapy may achieve the same effect as more protracted treatment, and trials to test this should be encouraged.
Final judgments must await long term follow up. Clinically useful advantages may yet emerge in some subgroups, defined in relation to menopausal state, spread of nodes, histological differentiation,26 and the like. But real benefit with adjuvant chemotherapy-as, for example, in paediatric tumoursrequires effective drugs. For early breast cancer there is nothing wrong with the concept; the problem is that the drugs themselves are so far just not good enough.
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